The trade name of Adalimumab is Humira. The abbreviation of Humira is for Human Monoclonal Antibody In Rheumatoid Arthritis. This biologic drug is used for treating rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis, and ulcerative colitis.
Here we just state some of the most important events during the study on Humira.
In 1993: researchers on BASF Bioresearch Corporation and Cambridge Antibody Technology that it includes government- under Medical Research Council and three academics collaboratively start to study on fully human anti-TNFα (TNFα stands for tumor necrosis factor-alpha) monoclonal antibody D2E7 and in 1999 the primary result of early clinical trials was announced. It was approved for rheumatoid arthritis in 2002, for Crohn’s disease on 200, and for psoriasis in 2007.
In 2013: Abbott was split and now AbbVie owned the rights of Humira.
In 2016: Genetic Engineering & Biotechnology News announced Humira, this pharmaceutical product as the best-selling drug for 2015 & 2016.
When you have an autoimmune disease your immune system faulty attacks your healthy body tissue instead of protecting your body from disease and infection. Humira is a TNF blocker medicine that is used to relieve pain and reduce inflammation and also fight infections by lower the ability of your immune system in these autoimmune diseases.
Humira can be used for rheumatoid arthritis and psoriatic arthritis and by the use of it patients can partly regain their ability to do their daily activities. It also can help patients with Crohn’s disease, psoriasis, and also ulcerative colitis.
2014 (December): Cadila Health care, the Indian drugmaker announced the launch of the first Humira biosimilar with the generic name of Exemption. It costs at a fifth of its American price.
2016 (January): Torrent Pharmaceuticals, the Indian drugmaker again, announced the launch of another bio-similar for Humira. The generic name of this bio-similar is Adfrar. It was the second biosimilar for Humira.
2016 (September): another bio-similar for Humira was launched by American drug-maker Amgen. The name of the new bio-similar is Amjevita.
Global Adalimumab Market: Geographical Segmentation
In some of the countries, there are well-structured regulatory frameworks, proper reimbursement coverage, and superior healthcare infrastructure. These elements affect the global market of Humira.
On the basis of geographical divisions, the keys segments in the global adalimumab market are:
- North America
- Western Europe
- Latin America
- Asia Pacific
- Eastern Europe
- Middle East
And the keys markets among them are North America (includes the U.S. and Canada) and Europe (which comprises Germany, Italy, France, Spain, and the Rest of Europe). Canada, The U.S, The UK, and Germany are the keys countries in the market of Humira.
Women as compared to males, lose more body calcium, so they are at higher risk of arthritis. And also Sedentary lifestyle causes a sizeable proportion of arthritis cases in North America and Europe. So the growth of the global Humira market is so significant.
Because of a cluster of fast-expanding developing nations in the Asia Pacific (includes China, Japan, South Korea, Taiwan, India, South-east Asia, Australia) the global markets in this region will see the strong promise of growth in the near future.
Rapidly developing healthcare infrastructure, rising disposable income and supportive government initiatives to reinforce healthcare division in the respective countries are factors that are driving the adalimumab market in the Asia Pacific. The largest and the most populated nations in the world are China and India and because of their growing population, it is expected that the demand for these anti-arthritis drugs witnessed significant growth in the near future.
If we considered its biological nature, this medication is expensive and this is the factor that is serving to counter the growth in its market.
On the basis of the type of disease, the global adalimumab market can be segmented as below: rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn’s disease, and ulcerative colitis, and now the rheumatoid arthritis segment grosses maximum revenue.
The revenue of pharmaceutical product Humira from 2011 to 2017is illustrated by this statistic. In 2017, AbbVie’s top product generated over 18 billion U.S. dollars of revenue.
The headquarter of Abbot is in Chicago, Illinois. This laboratory was a U.S.-based global pharmaceutical and healthcare products company that in January 2013 was separated into two companies: Abbott and AbbVie.
Abbott is a well-known pharmaceutical supplier and distributor that is now specialized in medical products, while AbbVie is responsible for research-based pharmaceuticals. The important thing here is that before using Humira, disclose any medical conditions and medication you are using.